clinical trial · NCT06271512
A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel
Beta-ThalassemiaNo Intervention
brief summary
The main aim of this study is to collect real-world longitudinal data on participants with β-thalassemia treated with betibeglogene autotemcel (beti-cel) in the post marketing setting. To assess the long-term safety, including the risk of newly diagnosed malignancies, after treatment with beti-cel and evaluate the long-term effectiveness of treatment with beti-cel.
started
Jan 23, 2024
primary completion
Dec 1, 2043
completion
Dec 1, 2043
last updated
Feb 11, 2025
official title
A Safety and Effectiveness Registry Study of Patients with Β-Thalassemia Treated with Betibeglogene Autotemcel (the Glostar Registry)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol